Praxis Precision Medicines has been granted a patent for compounds and compositions that can be used to prevent and treat neurological diseases and disorders, as well as conditions related to excessive neuronal excitability and gain-of-function mutations in genes like KCNT1. The patent also covers methods of treating these conditions. GlobalData’s report on Praxis Precision Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Praxis Precision Medicines, Peptide pharmacophores was a key innovation area identified from patents. Praxis Precision Medicines's grant share as of September 2023 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11773088B2) discloses a compound and its pharmaceutical composition for the treatment of various neurological diseases and disorders. The compound, which is selected from a specific group, can be administered to patients in need of treatment for conditions associated with excessive neuronal excitability or gain-of-function mutations of certain genes.
The patent claims also cover the use of a pharmaceutical composition containing the compound and a pharmaceutically acceptable excipient for the treatment of these neurological conditions. The method involves administering the composition to patients suffering from epilepsy, epilepsy syndromes, encephalopathy, or other genetic or pediatric epilepsy disorders. Additionally, the method can be used to treat cardiac dysfunctions, seizures, leukodystrophy, intellectual disability, and other related conditions.
Furthermore, the patent claims encompass the treatment of pain and related conditions such as neuropathic pain, acute pain, chronic pain, and migraine. Muscle disorders including myotonia, neuromyotonia, cramp muscle spasms, and spasticity can also be treated using the compound and pharmaceutical composition.
The patent claims extend to the treatment of itch and pruritus, ataxia or cerebellar ataxias, psychiatric disorders like major depression, anxiety, bipolar disorder, and schizophrenia. Additionally, the method can be used for the treatment of learning disorders, Fragile X, neuronal plasticity, and autism spectrum disorders.
The patent also covers specific neurological diseases and disorders associated with mutations in certain genes. These include epileptic encephalopathy with SCN1A, SCN2A, and/or SCN8A mutations, Dravet syndrome, generalized epilepsy with febrile seizures, infantile spasms, and Rasmussen encephalitis, among others.
In summary, the granted patent discloses a compound and its pharmaceutical composition for the treatment of a wide range of neurological diseases and disorders. The method involves administering the compound to patients in need of treatment, either alone or in combination with a pharmaceutically acceptable excipient. The patent claims cover various conditions including epilepsy, pain, muscle disorders, psychiatric disorders, and specific neurological diseases associated with gene mutations.
To know more about GlobalData’s detailed insights on Praxis Precision Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
